表紙
市場調査レポート

Stalevo/Comtan(パーキンソン病) - 予測と市場分析

Stalevo/Comtan (Parkinson's Disease) - Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 301431
出版日 ページ情報 英文 62 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
Stalevo/Comtan(パーキンソン病) - 予測と市場分析 Stalevo/Comtan (Parkinson's Disease) - Forecast and Market Analysis to 2022
出版日: 2014年03月31日 ページ情報: 英文 62 Pages
概要

パーキンソン病は、動作緩慢、筋硬直、振戦、姿勢の不安定で特徴づけられる進行性の症状です。2番目に高頻度の神経変性障害で、どの年齢層にも影響を及ぼす可能性があり、有病率は加齢とともに上昇し、高齢者によく見られます。動作緩慢には、ドーパミン療法がかなり効果的ですが、いくつかのアンメットニーズが残されています。

当レポートでは、パーキンソン病の治療薬であるStalevo/Comtanについて調査分析し、疾病の概要と治療ガイドライン、競合情勢、製品情報、主要国の売上予測などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
    • 病因
    • 病態生理
    • 予後
    • QOL
  • 症状

第4章 疾病の管理

  • 概要
  • 治療の概要
  • パーキンソン病の評価規模

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価
  • 製品プロファイル - COMT阻害薬

第6章 Stalevo/Comtan(entacapone)

  • 概要
  • 効能
  • 安全性
  • SWOT分析
  • 予測

第7章 付録

図表

目次
Product Code: GDHC392DFR

Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Comtan (entacapone) was developed by Orion for Parkinson's disease patients who experience end-of-dose wearing-off. The product, known as Comtan, is co-marketed with Novartis across the US, certain European markets, Brazil, and Japan. Orion has exclusive rights to the Nordic and Baltic countries, where the company is based, the UK, Ireland, and Germany, and is known as Comtess in these markets. Comtan/Comtess was first approved and launched in Europe in 1998, and launched a year later in the US. Additionally, entacapone is one of the active ingredients in Stalevo, a triple-combination pill with carbidopa, levodopa, and entacapone, co-marketed with Novartis.

Scope

  • Overview of Parkinson's disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Stalevo including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Stalevo for the top eight countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Brazil.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Parkinson's disease
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Stalevo performance
  • Obtain sales forecast for Stalevo from 2012-2022 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Brazil).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Overview
    • 4.1.1. Diagnosis - The UK Brain Bank Criteria
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
  • 4.2. Treatment Synopsis
    • 4.2.1. Dopaminergic Therapy Classes
    • 4.2.2. Treatment of Parkinson's Disease by Stage
    • 4.2.3. Other Treatment Options
  • 4.3. Parkinson's Disease Assessment Scales
    • 4.3.1. Unified Parkinson's Disease Rating Scale (UPDRS)
    • 4.3.2. Hoehn and Yahr Clinical Staging
    • 4.3.3. Other Clinical Assessments

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - COMT Inhibitors

6. Stalevo/Comtan (entacapone)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed Parkinson's Disease Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Compliance Assumptions
    • 7.4.5. Individual Drug Assumptions
    • 7.4.6. Generic Erosion
  • 7.5. Physicians and Specialists Included in this Study
  • 7.6. About the Authors
    • 7.6.1. Author
    • 7.6.2. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Parkinson's Disease
  • Table 2: UK Brain Bank Diagnostic Criteria
  • Table 3: Diagnosis and Treatment Guidelines for Parkinson's Disease
  • Table 4: Most Prescribed Drugs for Parkinson's Disease by Class in the Global Markets, 2014
  • Table 5: Dopaminergic Therapy in Parkinson's Disease
  • Table 6: UPDRS Clinical Assessment of Disease Severity
  • Table 7: Parkinson's Disease Assessment Scales Used in Clinical Trials
  • Table 8: Treatment of Motor Symptoms in Parkinson's Disease
  • Table 9: Leading Treatments for Parkinson's Disease, 2014
  • Table 10: Product Profile - Stalevo
  • Table 11: Product Profile - Comtan
  • Table 12: Stalevo/Comtan SWOT Analysis, 2014
  • Table 13: Global Sales Forecasts ($m) for Stalevo/Comtan, 2012-2022

List of Figures

  • Figure 1: Overview - L-dopa Metabolism and Inhibitor Classes
  • Figure 2: Overview - Treatment of Motor Symptoms of Parkinson's Disease
Back to Top